| |
Oxford, July 2007
|
“This was the kindest training
I have ever done. Because it was not only technical. It was specially
warm and human. I loved it. That is what our patients need: not
just technical, but warmth and humanity.”
Gisele Borelli-Montigny, Munich, Germany
(Oxford training, July 2007)
New drugs – Novel resistance pathways in HIV
12 & 13 July 2007, St. Catherine’s College, Oxford,
UK
Co-chairs: Dr Anna Maria Geretti and Dr Laura Waters
training | summary | programme | trainers | presentations | photos
 Mark
Atkins, United Kingdom
TOP OF PAGE
 David
Back, United Kingdom
David Back is a Professor of Pharmacology at the
University of Liverpool and established the Liverpool HIV Pharmacology
Group (LHPG) in 1987. The Liverpool Group have been at the forefront
of pharmacological research of antiretroviral drugs. Currently there
are numerous ongoing pharmacokinetic (TDM, IQ, drug-drug interaction,
pharmacological mechanisms of resistance) and pharmacogenomic (phenotype-genotype)
studies involving local, national and international collaborations.
They also run the highly successful web site www.hiv-druginteractions.org
and have recently joined with colleagues in Vanderbilt and Lausanne
to launch www.hiv-pharmacogenomics.org. David has authored or co-authored
more than 350 publications and is a former editor of British Journal
of Clinical Pharmacology.
TOP OF PAGE
 Charles
Boucher, Netherlands
Charles A. B. Boucher, MD, PhD, is Associate Professor
in the Department of Medical Microbiology at Utrecht University,
The Netherlands. Formerly, he was Head of the Antiviral Therapy
Laboratory at the Academic Medical Centre, Amsterdam. Dr Boucher
received his medical degree and PhD from the Faculty of Medicine
of the University of Amsterdam. Dr Boucher is an organizer of international
workshops, meetings and conferences, a consultant throughout Europe
and the United States, a reviewer for scientific journals and cochairman
of several international committees. Dr. Boucher is the national
coordinator of EuropeHIVResistance, a European network studying
transmission of HIV drug resistance in newly infected individuals.
TOP OF PAGE
 Patricia
Cane, United Kingdom
Patricia Cane is a Consultant Clinical Scientist
in the Health Protection Agency and Honorary Reader in Virology
at the University of Birmingham. She has undertaken research on
viral diversity and evolution for over 30 years, working on HIV
drug resistance for the past 10 years. She also leads a UK working
group on HIV genotypic resistance testing which provides a framework
for the translation of new assays into the routine use with guidelines,
training, data collection, and quality assurance.
TOP OF PAGE
 Bonaventura
Clotet, Spain
Dr. Clotet has been the Head of the HIV Unit of
Hospital Universitari Germans Trias i Pujol since 1986 and the Director
of the Retrovirology Laboratory "irsiCaixa" Foundation
since 1993. He received his medical degree of Medicine and Surgery
at the Universitat Autonoma de Barcelona, in 1976 and his PhD in
the investigation of surrogate markers for connective tissue diseases
in 1981. He is part of the organizing committees of several drug
resistance workshops and International Conferences on AIDS programmes,
and an active member of the Expert Commission for the evaluation
of research projects in the National Programme of Health and National
AIDS Programme. He is a member of the most prestigious organizations
and national and international committees (International AIDS Society,
EACS, EuroSIDA, GESIDA, Grup Assessor del Ministeri de Sanitat i
del Departament de Sanitat de la Generalitat de Catalunya, etc.).
.
TOP OF PAGE
 Anna
Maria Geretti, United Kingdom
Dr Anna Maria Geretti is a Consultant Medical Virologist
and Honorary Senior Lecturer at the Royal Free Hospital in London,
where she heads the Retrovirology laboratory and also works as a
physician with a specialist interest in HIV medicine, viral hepatitis
and genital herpes. She trained in Italy, the Netherlands and the
UK, and holds an MD in Medicine and a PhD in the virology and immunology
of HIV infection. She is an executive member of the British HIV
Association (BHIVA) Executive Committee and contributes to the production
of the BHIVA Treatment Guidelines. She is an advisor to the British
National Formulary and editor of the Journal of Antimicrobial Chemotherapy
and the Journal of HIV Therapy.
TOP OF PAGE
 Christine
Katlama, France
Christine Katlama is Professor in Infectious Diseases
since 1993 and Head of HIV/AIDS Clinical Unit in the Department
of Infectious Diseases, at the Pitie-Salpetriere Hospital in Paris.
She has been involved in the discovery of HIV-2 in 1986 and in all
major steps of antiretroviral therapy. She is the cofounder of the
international group, ORVACS, involved in anti-HIV immune intervention
and SOLTHIS with different ARV access programs in Africa.
.
TOP OF PAGE
 Brendan
Payne , United Kingdom
Dr Brendan Payne is a Specialist Registrar in Infectious
Diseases and Clinical Virology at Newcastle General Hospital, Newcastle-upon-Tyne
and James Cook University Hospital, Middlesbrough, UK as well as
a Research Fellow at Newcastle University. His main interest is
HIV infection. He holds a British Infection Society Clinical Research
Fellowship and is currently investigating aspects of the mitochondrial
toxicities of antiretroviral agents.
TOP OF PAGE
 Deenan
Pillay, United Kingdom
Deenan Pillay is Professor of Virology at UCL and
Honorary Consultant Virologist at UCLH. He also is Consultant Virologist
at Centre for Infections, HPA, Colindale. After training in Biochemistry
and Medicine, he undertook training in Medical Virology at St Thomas’
Hospital, and the Royal Free Hospital, in London before taking up
a Fellowship at University of California , San Diego. In 1994 he
was appointed to his first Consultant Virologist post in Birmingham,
where he became Head of the PHLS Antiviral Susceptibility Reference
Unit. In 2003, he moved to UCL, and has clinical and research interests
in HIV therapy, drug resistance and diversity.
TOP OF PAGE
 Jean-Claude
Schmit , Luxembourg
Jean-Claude Schmit, MD, PhD, is a clinician at
the National Service of Infectious Diseases in Luxembourg. Since
1996, he is also the head of the retrovirology laboratory, a research
laboratory focusing mainly on HIV drug resistance and more recently
on antibody engineering in the field of neutralising antibodies
to HIV infection. He received his medical degree from the University
of Louvain in 1988 and his PhD, for work on HIV drug resistance,
from the University of Leuven in 1998. He is a founding member of
the yearly European Workshop on HIV Drug Resistance and participates
in many European programmes on drug resistance such as SPREAD, Europe
HIV Resistance and EuroSida. Since 2006, he is also the director
of the Public Health Research Centre in Luxembourg.
TOP OF PAGE
 Laura
Waters, United Kingdom
Dr Laura Waters is a Research Fellow at The St
Stephen’s Centre, Chelsea & Westminster Hospital, London,
UK. She recently completed her Specialist Registrar training in
Genitourinary Medicine at Chelsea & Westminster. Dr Waters works
on antiretroviral pharmacokinetic studies and works and a variety
of Phase 3 clinical trials. She is currently leading a project assessing
the utility of different viral load assays in resource poor settings.
Dr Waters has published several articles in peer-reviewed journals
on a variety of HIV- and GU-related topics and has presented at
national and international scientific conferences.
TOP OF PAGE
 Mike
Youle, B Med Sci, MB ChB,
United Kingdom
After qualifying at Sheffield Medical School, UK,
Dr Mike Youle helped found the world-renowned Kobler Clinic in London
in 1986 as Clinical Trials Co-ordinator. Other than a 1-year stint
working as a Consultant for the World Health Organization’s
Global Programme on AIDS and the National Programme on AIDS in Kampala,
Dr Youle has devoted most of his career to the clinical care of
HIV patients. Since 1996 he has been the Director of HIV Clinical
Research at London’s Royal Free Hospital as well as an Honorary
Senior Lecturer in Public Health at its associated medical school.
His numerous professional activities currently include a visiting
professorship for Belgrade University and board/committee memberships
for organizations such as the International Association of Physicians
in AIDS Care, the British HIV Association and the MANON Therapeutic
Vaccine Programme. Dr Youle also serves as a trustee of the Red
Hot AIDS Charitable Trust and the National AIDS Manual, as well
as medical advisor to the Elton John AIDS Foundation.
TOP OF PAGE
|
